Gastric cancer-associated antigen MG7 (MG7-Ag)

MG-7 antigen (MG7-Ag) is a highly specific tumor-associated glycoprotein primarily identified in gastric cancer and its precancerous stages [1, 5]. It is characterized as a glycosylated protein sequence derived from the carcinoembryonic antigen (CEA) family and is significantly overexpressed in approximately 70-90% of gastric adenocarcinomas, while remaining nearly absent in normal gastric mucosa [5, 7]. This differential expression pattern makes MG-7 a critical biomarker for early diagnosis, screening, and monitoring the progression of gastric lesions such as atrophic gastritis and intestinal metaplasia [1, 16]. Beyond its role as a diagnostic marker, MG-7 serves as a therapeutic target for novel immunotherapies, including chimeric antigen receptor (CAR) T-cell therapies, dendritic cell (DC) vaccines, and DNA vaccines designed to activate a specific cytotoxic T-lymphocyte (CTL) response [3, 7, 9]. Research indicates that MG-7 may play a role in the tumor microenvironment by contributing to immune evasion and promoting cancer cell proliferation [1, 2]. While experimental therapies targeting MG-7 have shown promise in preclinical models and early-phase clinical trials, they face challenges common to other tumor-associated antigens, such as managing potential off-target effects and overcoming tumor-mediated immunosuppression [3, 10, 15].

Other names

MG-7 antigenMG7-AgMG7AgAG-7 antigenGastric cancer-specific antigen MG7

Targeting of gastric cancer cells through monoclonal antibodies, chimeric antigen receptors (CARs), or vaccine-induced cytotoxic T-lymphocytes (CTLs) to induce tumor cell lysis [2, 7, 8].